Kiora Pharmaceuticals (KPRX) to Release Quarterly Earnings on Tuesday

Kiora Pharmaceuticals (NASDAQ:KPRX) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $1.50 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Kiora Pharmaceuticals Price Performance

KPRX opened at $2.04 on Tuesday. The stock’s 50 day simple moving average is $2.13 and its 200 day simple moving average is $2.26. The firm has a market cap of $7.51 million, a price-to-earnings ratio of -0.98 and a beta of -0.80. Kiora Pharmaceuticals has a 1 year low of $1.76 and a 1 year high of $4.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in Kiora Pharmaceuticals by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares during the period. Two Sigma Investments LP purchased a new stake in Kiora Pharmaceuticals in the third quarter worth about $33,000. Citadel Advisors LLC bought a new position in shares of Kiora Pharmaceuticals during the third quarter valued at approximately $125,000. DRW Securities LLC increased its stake in shares of Kiora Pharmaceuticals by 199.2% during the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after purchasing an additional 73,417 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Kiora Pharmaceuticals during the fourth quarter valued at approximately $152,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kiora Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.